Diabetes Care 39 , e22e23 (2016)
Availability may vary by region, pharmacy supply, and clinical program structure
Supplements may enhance good foundations, but they don't replace them
Semaglutide doses typically range from 0.25mg to 2.4mg per week, while retatrutide can escalate up to 12mg per week
Older adults, those taking concurrent medications affecting gut motility, and individuals with slower metabolic rates may also show heightened responses
The Basics at a Glance Generic name: Retatrutide (development code: LY3437943) Manufacturer: Eli Lilly and Company Drug class: Triple agonist (GLP-1/GIP/glucagon receptor agonist) Administration: Once-weekly subcutaneous injection Dosing range: 2mg to 12mg weekly (gradual titration over 12+ weeks) Half-life: Approximately 6 days (reaches steady state in 45 weeks) FDA status: Phase 3 clinical trials (TRIUMPH program) Expected approval: 20272028 How Retatrutide Differs from Other GLP-1 Medications To understand retatrutide, it helps to see where it fits in the evolution of GLP-1 class medications